Viridian Therapeutics, Inc. (VRDN)

In October 2025, Viridian secured access to up to $889 million in potential capital, submitted its BLA for veligrotug to the FDA, accelerated the topline data readout for subcutaneous VRDN-003, and saw VRDN-006 show proof-of-concept IgG reduction in a Phase 1 trial. In February 2026, the company reported its fourth quarter and full-year 2025 financial results, including the PDUFA target action date for veligrotug and the advancement of VRDN-008 into a Phase 1 clinical trial. In March 2026, Viridian announced positive topline results from the Elegrobart Phase 3 REVEAL-1 clinical trial, but its stock fell by 38% due to investor concerns about its overall profile compared to existing standards of care. In April 2026, Viridian's shares further declined following Amgen's announcement of positive Phase 3 results for its competing TED drug, Tepezza.

There is no indication of demand seasonality for Viridian Therapeutics, Inc.'s products and services. Demand is primarily driven by disease prevalence and medical need rather than seasonal factors.

Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for patients with serious and rare autoimmune and rare diseases, particularly Thyroid Eye Disease (TED). Its major product candidates include veligrotug, a humanized monoclonal antibody targeting IGF-1R for IV administration, which has completed two Phase 3 clinical trials with positive topline data and has a BLA submitted to the FDA with a PDUFA target action date of June 30, 2026, and an MAA submitted to the EMA in January 2026. Elegrobart, a half-life-extended monoclonal antibody also targeting IGF-1R for SC administration, is being evaluated in two Phase 3 clinical trials, with positive topline results from the REVEAL-1 study announced in March 2026. The company also has a portfolio of Neonatal Fc receptor (FcRn) inhibitors and an anti-thyroid-stimulating hormone receptor (TSHR) program in development.

Viridian Therapeutics, Inc. has its corporate office in Waltham, MA, and an office in Boulder, CO. While primarily based in the U.S., the company is pursuing global opportunities, as demonstrated by the MAA submission for veligrotug to the EMA.

Viridian Therapeutics' brand reputation has been shaped by positive clinical advancements and competitive market pressures. Positive events include the successful BLA submission for veligrotug, positive topline data from Phase 3 trials for veligrotug, positive topline results from the Elegrobart Phase 3 REVEAL-1 clinical trial, and advancement of its FcRn inhibitor and TSHR programs. However, recent stock events indicate challenges to its market perception, including a stock drop in March 2026 despite positive REVEAL-1 data and a further decline in April 2026 following Amgen's announcement of stronger efficacy data for Tepezza.

Viridian Therapeutics, Inc. stock ownership is primarily institutional, with approximately 73.42% to 87.57% held by institutional investors, around 3.89% by insiders, and between 8.55% and 14.14% by public companies and individual investors. Major institutional owners include Fmr LLC, BlackRock, Inc., and Vanguard Group Inc. Logos Global Master Fund LP is a significant individual shareholder, owning 6.00 million shares, representing 5.87% of the company.